General
Preferred name
IMIPENEM
Synonyms
IMIPENEM HYDRATE ()
N-Formimidoyl thienamycin monohydrate ()
Imipenem monohydrate ()
IMIPENEM ANHYDROUS ()
Zienam-imipenem ()
Imipenem (monohydrate) ()
N-Formimidoyl thienamycin (monohydrate) ()
MK0787 (monohydrate) ()
Imipenem hydrate ()
MK-0787 ()
Imipemide ()
NSC-759901 ()
Imipenem monohydrate (h2o) ()
Imipenem ()
Imipenem (hydrate) ()
P&D ID
PD009459
CAS
74431-23-5
64221-86-9
Tags
covalent binder
natural product
drug
available
Approved by
PMDA
EMA
FDA
First approval
1985
Drug Status
approved
Drug indication
Bacterial infection
Antibacterial
Max Phase
Phase 4
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PHARMACODYNAMICS
Imipenem is a beta-lactam antibiotic belongings to the subgroup of carbapenems. Imipenem is active against aerobic and anaerobic Gram positive as well as Gram negative bacteria including Pseudomonas aeruginosa and the Enterococcus. Imipenem is administered with cilastatin to protect it from degradation by renal hydropeptidase.
DESCRIPTION
Imipenem is a broad-spectrum, semi-synthetic, intravenous β-lactam carbapenem derived from thienamycin.
(GtoPdb)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
0
Organisms
2
Compound Sets
21
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
CovBinderInPDB
CBR000276
CBR000277
CBR000449
CBR000450
CBR000609
CBR000610
CBR000611
CBR000612
CBR000613
CBR000614
CBR000863
CBR000864
CBR000888
CBR000896
CBR000897
CBR001350
CBR001351
CBR001352
CBR001353
CBR001545
CBR001546
CBR001604
CBR001631
CBR001737
CBR001738
CBR002051
CBR002052
CBR002059
CBR002061
CBR002130
CBR002131
CBR002132
CBR002133
CBR003655
CBR003656
CBR003734
CBR003735
CBR003736
CBR003737
CBR004541
CBR004681
CBR004682
CBR005148
CBR005149
CBR005150
CBR005151
CBR005797
CBR006170
CBR006766
CBR006770
CBR006973
CBR007160
CBR007442
CBR007443
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Guide to Pharmacology
MedChem Express Bioactive Compound Library
Natural product-based probes and drugs
NCATS Inxight Approved Drugs
NPC Screening Collection
Other bioactive compounds
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
83
Molecular Weight
299.09
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
4
Rotatable Bonds
7
Ring Count
2
Aromatic Ring Count
0
cLogP
-0.18
TPSA
113.72
Fraction CSP3
0.58
Chiral centers
3.0
Largest ring
5.0
QED
0.22
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
Microbiology&virology
Anti-infection
Target
PBPs
??-Lactamase
AmpC ??lactamase
antibiotic
Bacterial
¦Â-Lactamase
Indication
pneumonia, urinary tract infections, intra-abdominal infections, gynecologic infections, bacterial septicemia, bone and joint infections, skin infections, endocarditis
MOA
bacterial cell wall synthesis inhibitor
Biosynthetic Origin
Peptide (beta-Lactam)
Therapeutic Indication
Antibacterial
Therapeutic Class
Antimicrobial
Antibiotics
Source data
